{"schema_version":"1.0","type":"article","title":"Anthropic以83美元掛牌，製藥先賣速度","url":"https://drugnews.com.tw/articles/2026-11-23-anthropic-ipo-ai-drug-development.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-23-anthropic-ipo-ai-drug-development.md","lang":"zh-Hant","date":"2026-11-23","publish_at":"2026-11-23T08:00:00+08:00","updated_at":"2026-11-23","category":"商業分析系列","topic":"商業分析系列","tags":["Anthropic","Claude","AI 製藥","Mithril Medicine"],"summary":"Anthropic 的合作案例先交出可計時的工序成果，自有藥物仍在早期驗證。","key_points":["Anthropic 的合作案例先交出可計時的工序成果，自有藥物仍在早期驗證。","Enveda 的 89% 衡量人工文件審查工時。","英矽推進自有資產，晶泰以發現合作切入。"],"facts":[{"claim":"Anthropic 最終發行價","value":"83","unit":"美元／股","as_of":"","source":""},{"claim":"Anthropic 初步發行價區間","value":"70–78","unit":"美元／股","as_of":"","source":""},{"claim":"Anthropic Nasdaq 首日交易 ANT","value":"2026-11-19","unit":"美東日期","as_of":"","source":""},{"claim":"發行價估值","value":"1.5 兆","unit":"美元","as_of":"","source":""},{"claim":"截至 2026/9/30 前十二個月營收","value":"35.282 billion","unit":"美元","as_of":"","source":""},{"claim":"Anthropic 已公開披露收購 Mithril","value":"2026-10-27","unit":"公司公布日期","as_of":"","source":""},{"claim":"收購前 Mithril 為一人公司","value":"1","unit":"人","as_of":"","source":""},{"claim":"合作外部實驗室","value":"11","unit":"家","as_of":"","source":""},{"claim":"Mithril 罕見肌肉失養症計畫","value":"2","unit":"種疾病","as_of":"","source":""},{"claim":"單一計畫自構想到小鼠數據","value":"18","unit":"月，少於","as_of":"","source":""},{"claim":"最早人體試驗窗口","value":"2028 年底","unit":"公司有條件目標","as_of":"","source":""},{"claim":"公開合作案例","value":"6","unit":"家","as_of":"","source":""},{"claim":"單一 CAR-T 構件版本長度","value":"70%","unit":"約縮短","as_of":"","source":""},{"claim":"模型提出的抗體設計","value":"35,000","unit":"約","as_of":"","source":""},{"claim":"設計生成期間","value":"1","unit":"月，約","as_of":"","source":""},{"claim":"實作及測試的變體","value":"1,010","unit":"約","as_of":"","source":""},{"claim":"實作及測試所用時間","value":"10","unit":"週，約","as_of":"","source":""},{"claim":"製造文件測試量","value":"1,061","unit":"頁","as_of":"","source":""},{"claim":"人工製造文件審查工時","value":"89%","unit":"減少","as_of":"","source":""},{"claim":"Pleiades 早期流程測試範圍","value":"45","unit":"組","as_of":"","source":""},{"claim":"BMS 主管描述傳統初步分析用時","value":"數天","unit":"定性敘述","as_of":"","source":""},{"claim":"REC-1245 DAHLIA","value":"1/2","unit":"期；已有第一期早期資料","as_of":"","source":""},{"claim":"中國 GENESIS-IPF-3 首例給藥","value":"2026-09-10","unit":"三期公司公告","as_of":"","source":""},{"claim":"隨機二期試驗人數","value":"71","unit":"人","as_of":"","source":""},{"claim":"晶泰與 Pierre Fabre 公開合作","value":"2026-11-09","unit":"港交所披露日","as_of":"","source":""}],"sections":["01｜一人公司，十一家實驗室","02｜六家公司交出了什麼","03｜亞洲的兩種路線，差在誰把藥往後推","04｜等下一個藥物計畫走到哪裡","參考資料"],"references":[{"title":"最終招股書","source":"SEC EDGAR / Anthropic","date":"2026-11-18","url":"https://www.sec.gov/Archives/edgar/data/2130357/000162828026074944/anthropicpbc-424b4.htm"},{"title":"路演啟動公告","source":"Anthropic","date":"2026-11-10","url":"https://www.anthropic.com/news/roadshow-launch"},{"title":"掛牌與代號","source":"Nasdaq","date":"2026-11-19","url":"https://www.nasdaq.com/newsroom/anthropic-marks-ipo-at-nasdaq"},{"title":"六個案例與 Mithril","source":"Anthropic","date":"2026-10-27","url":"https://www.anthropic.com/research/early-progress-drug-development"},{"title":"Claude 企業協議","source":"Bristol Myers Squibb","date":"2026-05-20","url":"https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Strategic-Agreement-with-Anthropic-to-Position-Claude-Enterprise-as-the-Shared-Intelligence-Platform-Across-Its-Global-Operations/default.aspx"},{"title":"REC-1245 平台與臨床","source":"Recursion","date":"2026-05-06","url":"https://ir.recursion.com/news-releases/news-release-details/recursion-reports-first-quarter-financial-results-and-provides"},{"title":"DAHLIA 劑量遞增","source":"Recursion","date":"2026-11-02","url":"https://ir.recursion.com/news-releases/news-release-details/recursion-reports-third-quarter-2026-financial-results-and"},{"title":"TuneLab 上線","source":"Eli Lilly","date":"2025-09-09","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-launches-tunelab-platform-give-biotechnology-companies"},{"title":"合作實驗室","source":"Eli Lilly","date":"2026-01-12","url":"https://lilly.gcs-web.com/node/53651/pdf"},{"title":"Rentosertib 三期首例給藥","source":"Insilico Medicine","date":"2026-09-10","url":"https://insilico.com/news/isn1009261-insilico-medicine-doses-first-patient-genesis-ipf-3"},{"title":"Rentosertib 隨機二期","source":"Nature Medicine","date":"2025-06-03","url":"https://www.nature.com/articles/s41591-025-03743-2.pdf"},{"title":"晶泰港交所公告","source":"XtalPi / HKEX","date":"2026-11-09","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1109/2026110900037.pdf"},{"title":"合作方聲明","source":"Pierre Fabre","date":"2026-11-09","url":"https://www.pierre-fabre.com/en/news/ai-drug-discovery"},{"title":"發行價估值","source":"Nasdaq Economic Institute","date":"2026-11-20","url":"https://www.nasdaq.com/economic-institute/chartstopper-112026"},{"title":"首案關帳","source":"Anthropic","date":"2026-11-20","url":"https://www.anthropic.com/news/ipo-close"}],"images":[{"alt":"圖1｜AI插手的四段工作","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-development/figure-01.png"},{"alt":"11 · 家外部實驗室","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-development/inline-card-number-4f47d2cd6fef.png"},{"alt":"70% · CAR-T 構件約短","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-development/inline-card-number-720edac4c8fa.png"},{"alt":"圖2｜六家合作各自交付的工作","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-development/figure-02.png"},{"alt":"45 · 組標的與疾病配對","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-development/inline-card-number-34707855ccc4.png"},{"alt":"圖3｜模型公司、AI藥廠和大藥廠","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-development/figure-03.png"},{"alt":"71 · 名參與者","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-development/inline-card-number-d2e6b33f47b2.png"},{"alt":"圖4｜掛牌與Mithril研發的時間線","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-development/figure-04.png"},{"alt":"到 2027 年底，六家合作方至少一家會公開把 Claude 用於第二個具名資產的臨床規劃或申報，且 Mithril 尚未首例給藥。","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-development/inline-card-verdict-2f001a92cc85.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-development/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-23）。Anthropic以83美元掛牌，製藥先賣速度。https://drugnews.com.tw/articles/2026-11-23-anthropic-ipo-ai-drug-development.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-11-23-anthropic-ipo-ai-drug-development-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「Anthropic 的合作案例先交出可計時的工序成果，自有藥物仍在早期驗證」有哪些關鍵變化？","a":"Anthropic 的合作案例先交出可計時的工序成果，自有藥物仍在早期驗證。"},{"q":"「Enveda 的 89% 衡量人工文件審查工時」有哪些關鍵變化？","a":"Enveda 的 89% 衡量人工文件審查工時。"},{"q":"「英矽推進自有資產，晶泰以發現合作切入」有哪些關鍵變化？","a":"英矽推進自有資產，晶泰以發現合作切入。"}]}